City

Bethesda (1)

Guangzhou (1)

Condition

Leukemia, Acute Lymphocytic (ALL) (2)

Leukemia, Acute Myelogenous (AML) (2)

Leukemia, Chronic Myelogenous (CML) (1)

Myelodysplastic Syndrome (MDS) (1)

Myelodysplastic Syndromes (1)

Non-Hodgkin's Lymphoma (NHL) (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

National Cancer Institute (NCI) (1)

Zhujiang Hospital (1)

Collaborator

Shenzhen Geno-Immune Medical Institute (1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

Study Documents

Intervention Type

biological (1)

drug (1)

Funder Type

NIH (1)

Other (1)

Study Type

Interventional (2)

leukemia, acute myelogenous (aml)

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), MDS Trial in Guangzhou (Chimeric antigen receptor T cells,

Recruiting

Leukemia, Acute Lymphocytic (ALL)
+2 more

Chimeric antigen receptor T cells
peptide specific dendritic cell

Guangzhou, Guangdong, China

Zhujiang Hospital, Southern Medical University

Aug 1, 2021

Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML) Trial run by the NCI

Completed

Has Results

Leukemia, Acute Myelogenous (AML)
+4 more

WT1 Peptide-Pulsed Dendritic Cells
+7 more

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Mar 1, 2017